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Recent studies demonstrate that cAMP levels are
tightly controlled during demyelination and remyelina-
tion in Schwann cells as cAMP decreases to 8–10% of
normal following both sciatic nerve crush or permanent
transection injury and only begins to increase in the
crushed nerve after remyelination (Poduslo, J. F.,
Walikonis, R. S., Domec, M., Berg, C. T., and Holtz-Hep-
pelmann, C. J. (1995) J. Neurochem. 65, 149–159). To
investigate the mechanisms responsible for this change
in cAMP levels, cAMP phosphodiesterase (PDE) and ad-
enylyl cyclase activities were determined before and
after sciatic nerve injury. Basal cAMP PDE activity in
soluble endoneurial homogenates of normal nerve was
34.9 6 1.9 pmol/mg of protein/min (x 6 S.E.; n 5 10). This
activity increased about 3-fold within 6 days following
both injuries. Basal PDE activity remained elevated in
the transected nerve, but declined to 70 pmol/mg of pro-
tein/min in the crushed nerve at 21 and 35 days follow-
ing injury. Isozyme-specific inhibitors and stimulators
were used to identify the PDE families in the sciatic
nerve. The low Km cAMP-specific (PDE4) and the Ca
21/
calmodulin-stimulated (PDE1) families were found to
predominate in assays using endoneurial homogenates.
The PDE4 inhibitor rolipram also increased cAMP levels
significantly after incubation of endoneurial tissue with
various isozyme-specific inhibitors, indicating that
PDE4 plays a major role in determining cAMP levels.
PDE4 mRNA was localized by in situ hybridization to
cells identified as Schwann cells by colabeling of S100, a
Schwann cell specific protein. Adenylyl cyclase activity
declined following injury, from 3.7 pmol/mg of protein/
min in normal nerve to 0.70 pmol/mg/min by 7 days fol-
lowing injury. Both decreased synthesis and increased
degradation contribute, therefore, to the reduced levels
of cAMP following peripheral nerve injury and are
likely critical to the process of Wallerian degeneration.
The interactions between Schwann cells (SCs)1 and axons in
the peripheral nerve are very precisely controlled. Contact with
an axon induces numerous changes in SC biology including
proliferation (1, 2), production of basal lamina (3–7), wrapping
of myelin loops around the axon (8), the expression of myelin
specific proteins, such as P0 and the myelin basic proteins
(9–16), and the increased synthesis of lipid membrane compo-
nents (17–20). The maintenance of the myelin-forming pheno-
type is dependent on the continued contact between the axon
and SCs, as any interruption of this association leads to a
reversion of Schwann cells from a myelinating to a nonmyeli-
nating phenotype. Loss of contact leads to myelin breakdown,
down-regulation of myelin genes (14, 16, 21), proliferation of
SCs (22–24), and the expression of characteristic nonmyeli-
nated SC markers, such as nerve growth factor receptor, L1,
and glucocerebroside (19, 25, 26). Thus, Schwann cells exhibit
a remarkable capacity to alter their morphology and cellular
function as a result of contact with axons.
The precise signals induced in Schwann cells due to axonal
contact remain poorly defined. Previous work indicates a role
for the adenylyl cyclase/cAMP-dependent pathways using SCs
in culture (27, 28). Cyclic AMP elevation can at least partially
mimic the presence of the axon on cultured nonmyelinating
SCs. In these studies, embryonic or neonatal Schwann cells are
isolated and expanded in vitro by the addition of forskolin, a
stimulator of adenylyl cyclase (29, 30), and glial growth factor
(31). When these mitogens are removed and the Schwann cells
re-exposed to forskolin, they re-express low levels of myelin
genes (15, 32), myelin-specific membrane components galacto-
cerebroside and sulfatide (33–36), and display a more mature,
flattened phenotype (32).
Studies relating cAMP content to myelination have been
conducted by our laboratory using the in vivo models of crush
and permanent transection injury of the rat sciatic nerve. In
these models, the injury leads to degeneration of axons in the
distal segment of the nerve. The loss of axonal contact with SCs
leads to demyelination. In the permanently transected nerve,
axonal regrowth is prevented, and Schwann cells remain in a
nonmyelinating state. Following crush injury, degeneration
and demyelination occur as in the transected nerve, but axons
are allowed to regrow and are subsequently remyelinated.
Cyclic AMP content was measured at various time points
following both injuries and compared with myelin gene expres-
sion (37). The levels dropped to 10% of normal by 3 days
following both injuries, concurrently with the decrease in P0
gene expression, and remained very low in the nonmyelinating
transected nerve through 35 days after injury. In the crushed
nerve, cAMP levels did increase again starting at about 21 days
after injury, but reached only 27% of normal by 35 days after
injury, well after P0 re-expression in the crushed nerve, which
was 60% of normal expression by 14 days and 100% of normal
by 21 days following injury. Remyelination, therefore, seems to
precede cAMP recovery and suggests that cAMP may not play
a large role in inducing the process of myelination in the
peripheral nerve.
The importance of cAMP in inducing myelin transcripts in
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endoneurial segments was further tested using agents that
elevate cAMP. Forskolin alone increased cAMP significantly in
the normal nerve and in the regenerating crushed nerve, but
failed to increase levels in the transected nerve. Cyclic AMP
could only be elevated in the transected nerve by treatment
with 3-isobutyl-1-methylxanthine, a general inhibitor of phos-
phodiesterases (PDEs), as well as with forskolin (37). This
indicates that PDE inhibition is necessary to elevate cAMP
levels in nonmyelinating endoneurium following injury and
suggests that PDEs may play an important role in inactivating
this second messenger when Schwann cells are nonmyelinat-
ing. Treatment of endoneurial explants from normal, crush,
and transection injured nerves with these cAMP elevating
agents failed to increase myelin gene expression, further con-
firming the insufficiency of this messenger in inducing myelin
gene expression in vivo (37). Furthermore, recent studies by
Suter et al. (38) have identified two promoters on the periph-
eral myelin protein-22 gene. Promoter 1 is primarily active in
vivo for peripheral myelin protein-22. A TCAG sequence is
found near the peripheral myelin protein-22 transcription ini-
tiation site under the control of promoter 1. The same sequence
is found at transcription initiation sites in other myelin genes,
such as the P0 gene (25), myelin basic protein gene (39), and
proteolipid protein gene (40), which suggests a common control
mechanism. A second promoter controlling peripheral myelin
protein-22 expression is preferentially activated in cultured
SCs in response to forskolin, and thus the control of myelin
gene expression in cultured SCs may not mimic the control
mechanisms in vivo, and may confirm our data that cAMP is
not sufficient for myelin gene expression in the nerve.
Our previous study indicated that cAMP levels change dra-
matically following injury. Cyclic AMP levels primarily reflect
the net balance between synthesis and degradation of this
messenger. The present study quantifies adenylyl cyclase (AC)
specific activity before and after injury to assess how changes
in cAMP synthesis contribute to the changing levels of this
second messenger. ATP was quantified in normal and injured
nerves to determine whether changes in the concentration of
the AC substrate could alter cAMP levels. In addition, an
increase in PDE activity may wholly or partially be responsible
for the declining cAMP levels found during Wallerian degener-
ation, as PDE inhibition was required to elevate cAMP follow-
ing injury. The changes in PDE activity following injury were
measured, and the specific isozymes present in normal sciatic
endoneurium and those that were up-regulated following in-
jury were identified. Finally, in situ hybridization with a
PDE4-specific probe was performed to demonstrate the expres-
sion of this enzyme by Schwann cells.
MATERIALS AND METHODS
Animal Surgery—Animal surgery was conducted on male Sprague-
Dawley rats (200–225 g) under deep pentobarbital anesthesia. The
sciatic nerves were exposed and injured just below the sciatic notch,
either by crushing for 5 s with smooth forceps or by permanent transec-
tion with the ligated ends reflected 180° and sutured to adjacent muscle
to prevent axonal reentry (12). The distal segment was removed at
various time points following injury and the epineurium and peri-
neurium, which consist largely of fibers of connective tissue and epi-
thelial cells, were removed by the microdissection technique of Dyck et
al. (41). This technique allows exclusive study of the endoneurium,
which consists of the neural elements (axons, Schwann cells, and my-
elin) and supporting connective tissue. All animal use procedures were
in strict accordance with the NIH “Guide for the Care and Use of
Laboratory Animals” and were approved by the Mayo Animal Care and
Use Committee.
Phosphodiesterase Activity—PDE activities were determined by
measuring the degradation of [3H]cAMP in a two-step procedure (42–
44). Isolated endoneurium from normal or injured nerve was homoge-
nized in 20 mM TES, pH 7.4, 5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 5
mM b-mercaptoethanol, 0.1 mM leupeptin, 0.1 mM pepstatin, 0.1 mM
phenylmethylsulfonyl fluoride, and 0.1% Triton X-100 (45). In studies
measuring Ca21/CaM stimulated activity, the buffer included complete
protease inhibitor mixture without EDTA (Boehringer Mannheim),
supplemented with 0.1 mM leupeptin and 0.1 mM phenylmethylsulfonyl
fluoride, as we found this family of PDEs extremely sensitive to prote-
olysis. The homogenate was spun at 198,000 3 g for 30 min. The
supernatant and the pellet were separated. The pellet was resuspended
in homogenization buffer and the protein concentrations of both the
supernatant and pellet were measured using a Pierce bicinchoninic acid
protein assay (46). Basal PDE activity was measured by adding 2.5 mg
of protein in 10 ml of homogenization buffer to 100 ml of incubation
mixture (containing 50 mM TES buffer, pH 7.4, 0.1% bovine serum
albumin, 2 mM EGTA, 10 mM MgSO4, and 0.5 mM total cAMP, with 2.5
pmol of thin layer chromatography purified [3H]cAMP) (42) and incu-
bated at 30 °C for 7.5 min. In experiments examining the presence of
specific PDE2 isozymes, various PDE type-specific inhibitors and acti-
vators were included in the incubation mixture and compared with the
basal activity of matched samples without these diagnostic agents. In
testing for the presence of the Ca21/calmodulin (CaM)-dependent PDEs
(PDE1), the incubation mixture also contained 10 mg/ml CaM and 2.01
mM CaCl2, to obtain 10 mM free Ca
21 based on the chelation constant for
EGTA (47). Matching samples containing Ca21/CaM as well as 10 mM
Type I-specific PDE inhibitor 8-methoxymethyl-1-methyl-3-(2-methyl-
propyl)-xanthine (8-MeoM-IBMX) (Biomol Research Laboratories) were
also tested. The presence of cGMP-stimulated PDEs (PDE2) was tested
by including 5 mM cGMP in the incubation mixture (48–51) along with
10 mM 8-MeoM-IBMX and 3 mM cilostamide (N-cyclohexyl-N-methyl-
4(1,2-dihydro-2-oxo-6-quinohyloxy)butyramide; a kind gift from Otsuka
Pharmaceuticals, Osaka, Japan). The contribution of the cGMP-inhib-
ited isozyme toward total PDE activity was measured by including 3 mM
cilostamide (52, 53). Similarly, the activity of the low Km cAMP-specific
isozyme was determined by the addition of 3 mM rolipram (4-(3-cyclo-
pentyloxy-4-methylphenyl)-2-pyrolidone; a gift from Smith Kline
Beecham Pharmaceuticals, King-of-Prussia, PA) (52, 54) or 3 mM den-
bufylline. Following incubation, the samples were quickly frozen in a
dry ice and acetone slurry to stop the reaction. Fifty ml of PDE buffer (50
mM TES, pH 7.4, 10 mM MgSO4, 1 mM EGTA) was added, and the
samples boiled at 95 °C for 90 s to inactivate the PDEs. Upon cooling, 50
ml of 1 mg/ml snake venom (Ophiophagus hannah) was added, and the
mixture incubated for 30 min to convert the nucleotides to nucleosides.
One ml of cold carrier (containing 0.1 M each of adenosine, adenine,
hypoxanthine, and inosine) was added, and the samples were added to
QAE-Sephadex A-25 columns. The [3H]adenosine was eluted with 20
mM ammonium formate. The eluate was counted in a scintillation
counter, and the counts converted to picomoles of cAMP hydrolyzed/mg
of protein/min. Hydrolysis was kept to less than 10% of the substrate
and linearly proportional to incubation time and enzyme protein.
PDE assays were conducted on the supernatant and the 198,000 3 g
pellet from normal endoneurium and at various times following injury.
The homogenization buffer contained 0.1% Triton X-100 to promote
solubilization of PDEs (55), so most activity should be localized to the
soluble fraction. Activity in the pellet from normal endoneurium was
27% of total normal PDE activity, falling to just 20% of total activity by
35 days after crush injury and 7% of total activity at 35 days following
transection. Thus the majority of PDE activity was found in the soluble
fraction. Preliminary studies found no isozyme uniquely located to the
pellet, so further studies on the endoneurial PDE isozymes were con-
ducted solely on the soluble fraction.
Treatment of Sciatic Endoneurium with PDE Isozyme Inhibitors—
The distal segments of normal, and crushed or transected nerves 21
days following injury were removed, desheathed, and minced into
2–3-mm slices. The slices were incubated for 30 min at 37 °C in a
Krebs-Ringers II solution (110 mM NaCl, 5 mM KCl, 1 mM KH2PO4, 1.4
mM MgSO4, 4 mM NaHCO3, 12.8 mM glucose, 12.6 mM Na2HPO4, and
3.1 mM NaH2PO4) containing 30 mM rolipram, cilostamide, or 8-MeoM-
IBMX and with or without 100 mM forskolin (Calbiochem). Following
incubation, the slices were homogenized in 400 ml of cold 4 mM EDTA,
pH 7.0. Aliquots were removed for DNA quantification. The remaining
2 In this paper, the PDE isozymes are classified according to the
system proposed by Beavo (52, 84). In this system, PDE1 refers to the
family of PDE isozymes whose activity is dependent on Ca21 and
calmodulin; PDE2 is the family stimulated by micromolar concentra-
tions of cGMP; PDE3 are isozymes with low Km for cAMP and are
inhibited by cilostamide and cGMP but not inhibited by rolipram; PDE4
are isozymes with high affinity and selectivity for cAMP and are inhib-
ited selectively by rolipram.
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homogenate was boiled for 3 min and the precipitated proteins centri-
fuged at 15,800 3 g for 5 min in a refrigerated Eppendorf microfuge.
The supernatant was collected and assayed for cAMP using a kit from
Amersham. Fifty ml of [3H]cAMP (0.025 mCi: 0.9 pmol) was added to 50
ml of supernatant, followed by 100 ml of cAMP-binding protein dissolved
to the manufacturer’s specifications. The tubes were vortexed and kept
on ice for 2 h. One-hundred ml of suspended charcoal was then added to
adsorb any unbound cAMP. The tubes were centrifuged to pellet the
charcoal, and 200 ml of this supernatant was removed and placed into
scintillation vials for counting. The counts were compared with a stand-
ard curve constructed with known amounts of unlabeled cAMP, and the
results expressed as picomole of cAMP/mg of DNA.
In situ Localization of PDE4 mRNA—First strand cDNA was syn-
thesized from sciatic nerve total RNA with random hexanucleotide
primers using a cDNA synthesis kit (Boehringer Mannheim) following
the manufacturers directions. Polymerase chain reaction was per-
formed in a 50-ml volume containing 10 mM Tris-HCl, pH 8.3, 50 mM
KCl, 2.5 mM MgCl2, 0.001% gelatin, and 0.25 mM deoxynucleotides, 1
unit Taq polymerase, and 100 ng of cDNA. One mM rat PDE4/4B-specific
primers (sense, 59-GGCTGGGTACTCCCATAATCGG-39; antisense, 59-
GTAGAGAGGAGAACGTGGCGTTG-39) complementary to bases
1090–1111 (sense) and 1275–1296 (antisense) (56) were added. This
region is located near the beginning of the conserved catalytic region
and avoids the alternatively spliced regions near the 59 end. The PDE4
isogenes are approximately 70% identical in this region (57). Other PDE
families have a much lower homology in this region. Preliminary po-
lymerase chain reaction studies amplifying this region using primers
specific for PDE4D were not successful. The polymerase chain reaction
product of PDE4B was thus used for in situ hybridization. The polym-
erase chain reactions were performed for 1 min at 94 °C, 1 min at 55 °C,
and 1 min at 72 °C for 25 cycles. The amplified product was ligated into
pCRII plasmids (Invitrogen) and transformed into INVaF cells. Plas-
mids from individual colonies were isolated by miniprep (Qiagen) and
sequenced. Digoxygenin-labeled probes were created by SP6 (antisense)
and T7 (sense) run-off transcription using a Boehringer Mannheim kit.
Labeling efficiency was verified by dot-blot analysis of serially diluted
labeled transcripts. Dilutions giving equivalent signals for sense and
antisense were used for in situ probing of sciatic nerve sections.
In situ hybridization was conducted on sections of normal and 4-day
transected sciatic nerves. Sciatic endoneurial segments were fixed in
fresh 4% paraformaldehyde/PBS overnight followed by a PBS wash.
The tissue was dehydrated in a series of baths of increasing ethanol
concentrations followed by a xylene wash. The dehydrated tissue was
embedded in paraffin, sectioned in 5-mm sections, starting approxi-
mately 1 cm from the injury site, and baked on slides overnight at 45 °C.
The sciatic sections were deparaffinated by washing in xylene for 14
min followed by a series of 4-min EtOH baths of decreasing concentra-
tions (100 to 50%). The sections were then treated with 0.2 N HCl for 20
min followed by water and PBS rinses followed by incubation in 1 mg/ml
proteinase K for 30 min at 50 °C. After PBS and 23 SSC washes, the
tissues were incubated in 0.1 M triethanolamine with 0.25% acetic
anhydride for 10 min. Prehybridization was conducted by incubation in
hybridization buffer (containing 23 SSC, 10% dextran sulfate, 1 3
Denhardt’s solution, 50% formamide, and 0.1 mg/ml salmon sperm
DNA) for 2 h at 45 °C. Hybridization buffer containing diluted digoxy-
genin-labeled probes was then added. Coverslips were applied and the
section incubated for 24 h at 45 °C. The sections were washed in SSC,
and blocked in 100 mM Tris-NaCl with 1% bovine serum albumin for 30
min. The samples were then incubated with anti-digoxygenin antibod-
ies conjugated with alkaline phosphatase. Color development in NBT/
BCIP for 5 min followed.
S100 Immunolocalization—S100 was localized immunohistochemi-
cally in sections previously stained for PDE4 mRNA location. Immuno-
histochemical steps were used for S100 localization as the antidigoxy-
genin antibody treatment and color development steps during PDE4 in
situ hybridization were not RNase free, and the unhybridized S100
mRNA could become degraded and unsuitable for in situ hybridization.
Endogenous peroxidase activity was blocked by incubation of sections of
0.6% H2O2/MeOH for 30 min. Nonspecific binding sites were then
blocked by incubation in 20% normal goat serum, PBS, 0.05% Tween 20,
pH 7.4. The sections were incubated overnight in S100 primary anti-
body (Biogenex) diluted 1:15 in 10% normal goat serum/PBS. Following
a rinse in PBS, a biotinylated goat anti-rabbit antibody was added and
incubated for 1 h. Streptavidin/peroxidase was then added for 1 h,
followed by color development in tetrahydrochloride 3,39-diaminobenzi-
dine in 0.05 M Tris with 0.3% H2O2 for 5–10 min.
DNA Quantification—DNA was quantified by the method of Lipman
(58). Two-ml aliquots of sample homogenate were added to 2 ml of assay
buffer (containing 10 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, and
1.5 mM Hoechst Dye number 33258), and the fluorescence measured
using a TK-100 fluorometer (Hoefer Scientific Instruments). Calf thy-
mus DNA (Sigma) was used as a standard. The presence of PDE
inhibitors was not found to interfere with DNA determination.
Adenylyl Cyclase Assay—AC activity was measured in sciatic endo-
neurial homogenates from normal uninjured rats and 7 days following
crush injury. Isolated endoneurium were homogenized in 50 mM trieth-
anolamine buffer, pH 7.4, 5 mM MgCl2, 0.5 mg/ml leupeptin, and 0.5 mM
Pefabloc (Boehringer Mannheim). The homogenate was centrifuged for
20 min at 8,000 3 g at 4 °C. The pellet and supernatant were separated,
and the pellet resuspended in homogenization buffer. Protein concen-
trations of both the supernatant and pellet fractions were measured
using a bicinchoninic acid assay (Pierce) with bovine serum albumin as
standard. AC activity was measured using a two-column method (59–
61). Seventy ml of incubation mixture (containing final concentrations of
50 mM TEA, pH 7.4, 5 mM MgCl2, 0.1 mM cAMP, 0.1 mM ATP, 1 mg/ml
bovine serum albumin, 5 mM creatine phosphate, 2.5 units/100 ml of
creatine phosphokinase, 5 mM dithiothreitol, 500 mM 3-isobutyl-1-meth-
ylxanthine, 500,000 cpm of [a-32P]ATP and with or without 100 mM
forskolin) was added to each tube. 130–300 mg of protein in 30 ml of
homogenization buffer was added to the tubes and incubated at 30 °C
for 20 min. The tubes were then removed, 100 ml of stop solution
(containing 50 mM triethanolamine, pH 7.4, 2% SDS, 40 mM ATP, 1.4
mM cAMP, and approximately 80,000 cpm/100 ml of [3H]cAMP to meas-
ure recovery) was added, and the tubes placed on ice until they could be
boiled for 90 s. The [32P]cAMP formed was then separated from the
remaining ATP using the sequential double column method. The sam-
ple was first placed onto a Dowex AG 50W-X12 column (0.8 3 3.0 cm)
that had been conditioned with 1 M HCl and washed with H2O. The
samples were washed with 2 ml of H2O to remove the majority of the
[32P]ATP, and the Dowex columns placed over neutral alumina columns
(Activity grade Super 1, Type WN-6; Sigma). The sample was further
eluted from the Dowex onto the alumina with 8–10 ml of H2O. Once the
eluate from the Dowex had drained through the alumina, the cAMP was
eluted from the alumina with 7 ml of 100 mM Tris, pH 7.5. The samples
were counted for both 3H and 32P, and the counts converted to picomole
of cAMP/mg of protein/min. Results reported are from the pellet fraction
as 87.4 6 0.3% of the total activity was found in this fraction.
ATP Quantification—ATP was assayed in sciatic nerve homogenates
from normal rats and at 21 and 35 days following transection injury.
ATP was quantified by the bioluminescent methods of Strehler (62)
using an ATP bioluminescence kit (Sigma) according to the manufac-
turers instructions. One nerve was homogenized in 400 ml of cold sterile
H20, and a small aliquot was removed for protein determination as
described above. Four-hundred ml of cold 0.8 N HClO4 was added, and
the sample rehomogenized. The sample was spun 15,800 3 g for 15 min.
The supernatant was removed, and 400 ml of 0.8 N KOH was added to
neutralize the acid. The sample was centrifuged again at 15,800 3 g
and 400 ml of 0.3 M Na2HPO4 was added to the supernatant. This
sample was diluted 1:5 in H2O for ATP determination. ATP standards
were diluted in an identical solution, and the results were normalized to
total protein.
RESULTS
PDE Activity in Rat Sciatic Endoneurium following Injury—
The PDE specific activity assayed under basal conditions (with
no inhibitors or modulators added) in the supernatant of nor-
mal endoneurial homogenate was 34.9 6 1.9 pmol/mg of pro-
tein/min (x 6 S.E.; n 5 10) (day 0, Fig. 1). This activity signif-
icantly increased by 2 days following both crush and
transection injuries, and continued to increase 3–3.5-fold over
normal to 105–129 pmol/mg of protein/min within 6 days of
both injuries. In the nonmyelinating transected nerve, PDE
activity remained elevated, at 105–110 pmol/mg/min at 21 and
35 days following injury. In the crushed nerve, on the other
hand, PDE activity declined as remyelination occurred, falling
from a high of 128.8 6 11.7 pmol/mg/min at 6 days to 76.1 6
11.7 pmol/mg/min by 21 days following injury. PDE activity
remained at this level through 35 days following crush injury.
Identification of the Specific PDE Isozymes using Modulators
and Inhibitors—PDE activity was measured on paired samples
to compare activity with and without stimulators or inhibitors.
The PDE1 isozyme is a Ca21/CaM-stimulated isozyme. The
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presence of this family was tested by the addition of 10 mM Ca21
and 10 mg/ml CaM to the incubation medium and comparing
the activity to paired samples incubated without Ca21/CaM.
The change from basal activity was tested in normal homoge-
nates, and at 7 and 21 days following both crush and transec-
tion injury. The addition of Ca21/CaM more than doubled PDE
activity in the normal nerve (Fig. 2A). The Ca21/CaM stimu-
lated specific activity increased 7 days after injury (Table I),
but declined in both the crushed and transected nerves by 21
days. The Ca21/CaM stimulated activity represented a smaller
percentage increase in activity after injury (Fig. 2A) due to the
higher basal PDE activity. The increased PDE activity due to
Ca21/CaM was completely blocked by the addition of the PDE1
specific inhibitor 8-MeoM-IBMX, verifying that the increased
activity was due to PDE1 stimulation. Thus the PDE1 family is
present and may increase after injury. However, the high ac-
tivity is not sustained in the nonmyelinating transected nerve.
The presence of the cGMP-stimulated isozyme (PDE2) was
tested by incubating identical samples with and without 5 mM
cGMP in the incubation mixture. This represents a 10-fold
excess of cGMP over cAMP. Cilostamide and 8-MeoM-IBMX
were included in samples both with and without cGMP. These
inhibitors were included to block the activity of the other PDEs
that either are inhibited by cGMP or hydrolyze cGMP (63).
Both inhibitors were found to be necessary, as cGMP decreased
cAMP hydrolysis if either inhibitor was omitted from the reac-
tion mixture. With the inhibitors present, any change in PDE
activity represents the net effect of cGMP on the PDE2
isozymes. Cyclic GMP was not found to stimulate cAMP PDE
activity at any time point (data not shown), and thus the
presence of PDE2 isozymes could not be demonstrated. As a
positive control, stimulation of cAMP PDE activity in total
brain homogenate by cGMP was tested. A stimulation of activ-
ity by 71% was found (data not shown), similar to previous
descriptions (51, 64).
The activity of the cGMP-inhibited isozymes was tested by
the inclusion of cilostamide, a specific inhibitor of PDE3
isozymes. In the normal nerve, 3 mM cilostamide (maximum
inhibitory dose) decreased PDE activity by 6.8 pmol/mg/min
(Table I), a 19% decrease (Fig. 2B). The PDE3 activity in-
creased little following injury (Table I), and thus represents a
smaller percentage of the total activity following injury, typi-
cally from 9 to 11% (Fig. 2B). Thus, while the PDE3 family is
present in peripheral nerve, it appears to contribute minimally
to the overall increase in PDE activity that occurs during
demyelination.
The contribution of the low Km cAMP-specific (PDE4)
isozyme to total PDE activity was tested using the selective
inhibitors rolipram and denbufylline. Three mM rolipram (max-
imum inhibitory dose) was added to paired samples and the
mean % inhibition is shown (Fig. 2B). In normal nerve, rolip-
ram decreased activity by an average of 12.4 pmol/mg/min, a
34% decrease. Following injury, rolipram continued to inhibit
activity by about 25 to 43 pmol/mg/min (Table I), a decline from
24 to 37% (p , 0.001 at all time points). The specificity of
FIG. 1. Basal cAMP phosphodiesterase activity following
crush and transection injury to rat sciatic nerve. Basal activities
using 0.5 mM cAMP as substrate were assayed in soluble fractions of
normal nerves (Day 0) and following injury without added inhibitors or
modulators in media containing 2 mM EGTA. (x¯ 6 S.E.). * Values
significantly different from normal by t test. *, p , 0.05; **, p , 0.01;
***, p , 0.001; Days 1–3: n 5 3 per time point; all others: n 5 7–10 per
time point).
FIG. 2. The effect of isozyme specific stimulators or inhibitors
on cAMP PDE activity before and after injury. A, the effect of Ca21
and calmodulin on phosphodiesterase activity (PDE1). Paired samples
were tested with or without 10 mM Ca21/calmodulin and 10 mg/ml
calmodulin. Matching samples with Ca21/calmodulin and 10 mM 8-me-
thoxymethyl-IBMX were also tested. B, the effect of cilostamide inhibi-
tion of PDE3 and inhibitors of low Km-cAMP specific phosphodiester-
ases (PDE4) on cAMP PDE activity before and after injury. PDE
activity was tested on paired samples with or without 3 mM cilostamide,
an inhibitor or cGMP-inhibited (PDE3) enzymes, or with or without 3
mM rolipram or 3 mM denbufylline, inhibitors of low Km cAMP-specific
phosphodiesterases (PDE4). Denbufylline was only tested in normal
and 7 day injured samples. The % difference of each paired sample 6
inhibitor or stimulator was calculated and the mean % difference is
shown (x¯ 6 S.E.). A, n 5 5–7; B, n 5 7–10). *, values significantly
different from paired samples without inhibitor or stimulator by paired
t test. *, p , 0.05; **, p , 0.01; ***, p , 0.001.
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inhibition by rolipram was verified by also testing PDE inhibi-
tion by denbufylline, an unrelated PDE4 inhibitor, in homoge-
nates from normal nerve and 7 days following both injuries
(Fig. 2B). Thus the low Km cAMP-specific isozyme is a predom-
inant isozyme present in the rat sciatic nerve, and the in-
creased activity of this family probably largely contributes to
the overall increase in PDE activity following injury.
cAMP Changes in Endoneurial Explants due to Inhibition of
Specific Isozymes—The role of individual PDE families in hy-
drolyzing cAMP in sciatic endoneurium explants was tested.
The effects on cAMP content due to specific PDE isozyme
inhibition under conditions of basal AC activity was tested by
incubating endoneurium from normal nerve, and nerves 21
days following crush and transection injury for 30 min in solu-
tions of Krebs-Ringers and 30 mM rolipram, cilostamide, or
8-MeoM-IBMX, an inhibitor of the PDE1 family. The effects of
these inhibitors using identical solutions containing 100 mM
forskolin (PDE inhibition under AC stimulated conditions) was
also tested. The effects of PDE inhibition under basal condi-
tions are shown in Fig. 3A. In the normal nerve, cAMP levels
were 2.8 6 0.3 pmol/mg of DNA. These levels were elevated
significantly only by rolipram to 5.8 pmol/mg of DNA. Rolipram
similarly elevated cAMP to a greater extent than the other
inhibitors in the crushed (remyelinating) and transected (non-
myelinating) nerves. A similar effect of rolipram was found
following AC stimulation by forskolin. In normal nerve, cAMP
levels in endoneurium incubated in Krebs-Ringer and forskolin
were 221 6 22.8 pmol/mg of DNA (Fig. 3B). The addition of
rolipram slightly increased cAMP to 273 6 12.6 pmol/mg of
DNA. The other inhibitors failed to increase cAMP. In the
crushed nerve, rolipram increased cAMP levels from 18.0 6 3.0
pmol/mg of DNA to 51.5 6 3.2 pmol/mg of DNA (p , 0.001).
Cilostamide and 8-MeoM-IBMX increased cAMP in nonsignif-
icant amounts. In the transected nerve, similarly, rolipram
increased cAMP from 0.5 6 0.1 pmol/mg of DNA to 8.9 6 1.4
pmol/mg of DNA (p , 0.001). Cilostamide and 8-MeoM-IBMX
increased cAMP by smaller amounts. The rolipram-inhibitable
isozymes, therefore, seem to be the predominantly active form
in endoneurial explants. PDE activity in the normal nerve is
quite low, and thus it is not surprising that the increase in
cAMP due to rolipram in normal AC-stimulated nerve was not
FIG. 3. The effect of PDE isozyme-
specific inhibitors on cAMP accumu-
lation in endoneurial explants from
normal nerve and 7- and 21-day
crushed or transected nerves under
basal (A) and forskolin-stimulated
(B) conditions. A, isolated endoneurial
segments were incubated in Krebs-Ringer
alone (control) or with 30 mM rolipram,
cilostamide, or 8-MeoM-IBMX for 30 min,
followed by cAMP quantification. B, iso-
lated endoneurial segments were incu-
bated with PDE inhibitors 1 100 mM for-
skolin for 30 min, followed by cAMP
quantification (n 5 7–12 per time point).
**, p , 0.01; ***, p , 0.001) versus Krebs-
Ringer by t test. M, Krebs; f, cilostamide;
p, rolipram; o, 3-MeoM-IBMX.
TABLE I
Activities of phosphodiesterase 1, 3, and 4 in sciatic endoneurium before and after injury
x 6 S.E., pmol/min/mg protein; n 5 4-10.
Normal
Crush Transection
7 Days 21 Days 7 Days 21 Days
PDE1 102.8 6 8.1*** 187.1 6 13.8*** 85.4 6 11.2*** 154.6 6 8.2*** 49.6 6 7.6**
PDE3 6.8 6 1.4 13.7 6 2.7 9.1 6 2.4 11.2 6 2.5 8.3 6 2.9
PDE4 12.4 6 2.7 42.9 6 6.0*** 28.7 6 4.8** 31.2 6 3.7*** 24.9 6 3.0**
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significant, as it was after crush and transection injuries when
PDE activity is much higher.
In situ Localization of PDE4—To verify that the PDE4 ex-
pression is in SCs, PDE4B mRNA was localized in sciatic
sections by in situ hybridization. The sciatic sections were first
probed for PDE4B mRNA location. The sections were then
photographed, followed by immunohistochemical localization
of S100, an SC specific protein (65) on the same sections.
Numerous cells scattered throughout the sciatic section were
heavily stained following in situ hybridization of PDE4B
mRNA (Fig. 4). The strongest in situ labeling would be ex-
pected in SCs sectioned through their cytoplasm, where PDE4
mRNA would be located. Other cells in which the plane of the
section did not traverse the cytoplasm would not be as strongly
stained. The hybridization pattern is consistent with these
expectations. The cells which stained darkest for PDE4 also
were heavily stained by S100 immunohistochemistry. S100
immunoreactivity was primarily localized to SC cytoplasm,
with occasional light staining of SC membranes. In biochemical
studies, S100 has been found to associate with cytoplasmic
fractions of nerve homogenates, with a small percentage found
to be tightly associated with a particulate, membrane-associ-
ated fraction (66, 67). Some slight S100 staining was localized
to myelin, similar to immunohistochemical localization re-
ported by others at both the light and electron microscopic
levels (68–70), where the PDE4 message would not be ex-
pected. Nearly all cells that stained for PDE4B also stained for
S100. An occasional cell that stained heavily for S100 partially
obscured a weaker signal for PDE4, but comparison of pictures
taken after PDE4B in situ hybridization and prior to S100
immunostaining verifies that PDE4 is found in these cells.
Only cells that strongly labeled for S100 gave a strong PDE4
signal, indicating that SCs are the principle source of PDE
activity and there is not another sciatic element with extensive
PDE expression. In situ hybridization using sense strand tran-
scripts did not give any color reaction (data not shown).
AC Activity following Injury—Another factor contributing to
the decline in cAMP levels in distal endoneurium following
injury could be decreased synthesis by ACs. The activity of AC
in the distal endoneurium was measured in membrane frac-
tions from normal nerve and 7 days following crush injury, a
time when cAMP is lowest (37). Basal AC activity, without
forskolin added, in normal nerve was 3.7 6 0.3 pmol/mg of
protein/min (n 5 10). At 7 days following injury, basal activity
was just 0.7 6 0.08 pmol/mg/min (n 5 15), only about 19% of
normal. Forskolin stimulated AC activity in the normal endo-
neurium by 4.6-fold, to 17.1 6 0.8 pmol/mg/min (n 5 10), while
following injury, forskolin stimulated activity to 5.0 6 0.6 pmol/
mg/min (n 5 15), which is 29% of normal forskolin stimulated
values. The values for normal nerve both with and without
forskolin treatment are very similar to those found by Shindo et
al. (71). Thus it is evident that a decrease in AC activity and an
increase in PDE activity both contribute to the decreased cAMP
levels found in the distal endoneurium following injury.
ATP Quantification following Injury—One possible limiting
factor in AC activity in vivo could be ATP concentration. If AC
substrate levels declined following injury, it could contribute to
the overall decrease in cAMP levels. ATP concentration was
thus determined in normal endoneurium, as well as at 21 and
35 days following transection injury, times when cAMP levels
are very low (37). In normal nerve, ATP concentrations were
519 pmol/mg of protein. A similar value was found at 21 days,
but by 35 days, ATP levels were somewhat lower at 362
pmol/mg of protein. These fluctuations in ATP are probably not
sufficient to cause the decline in AC activity following injury.
DISCUSSION
Cyclic AMP levels have been previously shown to change
dramatically following injury to the sciatic nerve (37). The
results from the present series of experiments indicate that
these variations in cAMP levels are the result of changes in
rates of both synthesis and degradation of this second
messenger.
A 3–3.5-fold increase in phosphodiesterase activity occurs
shortly after injury. This activity remains elevated in the
transected nerve, while it declines to a level that is still twice
normal activity by 21 and 35 days following crush injury. This
increase in PDE activity occurs at the time when cAMP levels
are declining following injury (cf. Ref. 37; Fig. 1). The continu-
ing elevated PDE activity in the transected nerve correlates
well with the low endogenous levels of cAMP that persist fol-
lowing this injury. In the crushed nerve the partial decline in
PDE activity that occurs at 21 and 35 days following injury
correlates well with the partial recovery in cAMP levels that
occur at this time. Cyclic AMP levels did not return to normal
levels even at 35 days following injury (37) which may be due to
the failure of PDE activity to decline to normal levels at this
time point. These data suggest that cAMP levels are tightly
regulated following injury.
The predominant isozymes of PDE in the sciatic endo-
neurium both before and after injury appear to be the low Km
cAMP-specific (PDE4) isozyme and the Ca21/CaM-stimulated
(PDE1) isozyme. The activity of both these families was up-
regulated following injury, although the contribution of the
PDE1 isozyme was slightly lower as a percentage of the total
activity after injury. The PDE4 activity increased sufficiently
FIG. 4. Colocalization of PDE4 mRNA and S100 protein in sci-
atic nerve 4 days following crush injury. A, in situ localization of
PDE4 (blue) and immunohistochemical localization of the SC marker
S100 (brown) in transverse section of sciatic nerve 4 days following
crush injury. Only cells that strongly stained for S100 were also
strongly stained for PDE4. (3 40). B and C, higher magnification (3
100) of the boxed region in A showing in situ localization of PDE4 (B),
and the same region after both in situ localization of PDE4 and S100
immunohistochemistry (C).
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to maintain a similar percentage of the total activity both
before and after injury. This was in contrast to the cilostamide
inhibitable (PDE3) activity which was just 19% in normal
nerve and 9–11% of basal activity following injury. The pres-
ence of the cGMP-stimulated isozymes could not be demon-
strated, as there was no increase in PDE activity in the pres-
ence cGMP.
The importance of the PDE4 family in hydrolyzing cAMP in
sciatic endoneurium was verified by studies using intact endo-
neurial tissue. Incubation of endoneurial explants with type-
specific inhibitors showed that PDE4 inhibition caused a
greater elevation in cAMP than inhibition of the other
isozymes. Thus the activity of this isozyme has a major role in
hydrolyzing cAMP in intact endoneurium. The elevation in
cAMP by rolipram in the presence of forskolin in the normal
nerve was greater than the response to other inhibitors, but
was not significant as it was following injury (Fig. 3). PDE
activity in normal nerve was lower than in the injured nerve,
and thus inhibition of PDE activity in the normal nerve would
likely not have as great an effect on cAMP levels as it would
following injury.
Another determining factor of cAMP levels is the rate of
synthesis by adenylyl cyclases. We, therefore, measured AC
activity in normal nerve and 7 days following crush injury,
when cAMP levels are very low (37). AC activity declined to
about 19% of normal by 7 days following injury. Thus a decline
in synthesis as well as an increase in hydrolysis contributes to
the low levels of cAMP following injury.
Numerous changes occur in the distal endoneurium follow-
ing injury. Axonal degradation occurs rapidly, concomitant
with infiltration of the distal segment by macrophages (72, 73),
the transformation of the SCs from a myelinating to a nonmy-
elinating state, and proliferation of SCs (22, 24). Thus the
cAMP changes reported by Poduslo et al. (37) reflect the sum of
the changes in cAMP levels of all the constitutive elements
remaining in the endoneurium, and the results of the present
study also must be interpreted with regard to the changes
occurring in the cellular elements.
The change in AC activity may occur in several different
cellular elements of the endoneurium. The activity changes
may reflect altered AC activity in SCs, as axolemmal constit-
uents have been proposed to stimulate SC ACs (2). The total
activity, however, probably also reflects declines in axonal AC.
The role of the axon with regard to AC transport has previously
been investigated. Bray et al. (74) observed that constrictions
for 20 h around chicken sciatic nerve led to accumulations of
AC activity by 266% immediately proximal to the constriction,
while the AC activity immediately distal to the constriction
changed little in 20 h. The accumulation proximal to the con-
striction was interpreted as being the result of blocked axonal
transport of AC. Longer term studies were not conducted, but if
AC transport is blocked, it would be expected that AC activity
in the distal segment would decline. Carlsen (75) and Carlsen
and Anderson (76) similarly showed an accumulation of AC
activity proximal to a ligature places around frog sciatic nerve.
Thus the decline in AC activity that we have demonstrated
may be due in part to the loss of the axon with its contributing
AC activity distal to the crush injury. However, there may also
be changes in AC expression and activity that occur in the
cellular elements in the distal segment. A down-regulation of
AC activity may accompany the increased PDE activity to
lower the cAMP concentration in some of the remaining cellu-
lar elements.
The principle source of PDE activity is due to PDE expres-
sion in SCs. This is indicated by several lines of evidence. First,
in situ localization of PDE4 mRNA (Fig. 4) demonstrated prom-
inent staining of SC, identified by costaining for S100, a SC
specific protein. There were no cells that were heavily labeled
for PDE4 that were not also stained for S100. Furthermore,
SCs account for 85–90% of the cells present by 35 days follow-
ing transection (77), thus the PDE activity probably largely
reflects the activity of SCs.
Macrophages infiltrate the distal segment, and thus could
contribute to an increased total PDE activity. However, at 35
days following transection, endoneurial macrophages account
for only 1–3% of total cell area (77), so these cells probably do
not contribute significantly to the total PDE activity. Further-
more, the differences that are seen between the transected
nerve and the remyelinating crushed nerve 21 and 35 days
following injury make it likely that the changes in PDE activity
reflect changes in SCs as they remyelinate, and not changes
due to macrophages. Further studies to eliminate the contri-
bution of macrophages have been conducted using explants of
sciatic nerve. Sciatic endoneurium from normal nerve was in-
cubated from 1 to 4 days in vitro. This paradigm allows axonal
degeneration and SC dedifferentiation to occur without an in-
vasion by circulating macrophages (78). Cyclic AMP levels were
measured in these explants cultured for 1–4 days and com-
pared with cAMP changes that occur following crush injury in
vivo.3 The levels of cAMP in vivo decline following crush injury
to just 11% of normal by 4 days following injury (37). Similarly,
cAMP levels dropped in endoneurial explants to 33% of normal
by 4 days of culturing. The similar decline in cAMP levels
observed in vivo and in endoneurial explants suggests that
invading macrophages do not contribute to the increased PDE
activity observed in vivo.
It is not known what mechanisms may be controlling PDE
activity in SCs. The up-regulation of PDE activity may be
intrinsically controlled during differentiation of SCs. There is
also mounting evidence that PDE levels can be actively con-
trolled by extracellular ligands. For example, in the C6 glioma
cell line, follicle-stimulating hormone leads to an increase in
message levels of some forms of PDE4 (56). Insulin, which acts
through a receptor tyrosine kinase, also exerts metabolic ef-
fects via phosphorylation and activation of PDE3 (79, 80). The
up-regulation of PDEs that occurs in the distal nerve after
injury may be under some form of hormonal or growth factor
influence. As demyelination occurs, some receptor may be up-
regulated resulting in increased responsiveness of PDEs to
external stimuli. Conversely, cAMP changes in Schwann cells
can modulate the expression of growth factor receptors (81),
and thus the active regulation of cAMP by PDE activation may
affect the response of SCs to growth factors by controlling
receptor expression.
A further role for PDEs in the demyelination processes has
been suggested in experimental autoimmune encephalomyeli-
tis, an animal model for multiple sclerosis (82, 83). Encephalo-
myelitis is induced by immunization of susceptible animals
with central nervous system tissue. This immunization pro-
vokes a T-lymphocyte autoimmune attack against central nerv-
ous system myelin, which involves participation of cytokines.
Rolipram has been demonstrated to suppress the production of
cytokines by autoreactive T cells (82). Through this mecha-
nism, rolipram has been found to prevent the lesions found in
encephalomyelitis. PDEs may well play a role in demyelination
in peripheral nerve as well, either through mechanisms in the
SCs themselves, or by altering the influence of other cells on
demyelination.
The characterization of PDE activity in the distal endo-
neurium following injury with the subsequent changes in my-
3 J. F. Poduslo, et al, manuscript in preparation.
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elination indicate that PDE activity is related to the processes
of demyelination and remyelination. It is possible that the
active removal of cAMP in SCs via an up-regulation of PDEs
may lead to demyelination. Conversely, a down-regulation of
PDE activity may then be an obligate step preceding the proc-
ess of myelination. The identification of the specific isozymes
present will allow us to selectively manipulate their activity to
investigate the role of these PDE isozymes in these processes.
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